Literature DB >> 3154528

Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction.

B Lerer1, A Ran, M Blacker, H Silver, M P Weller, D Drummer, B Ebstein, A Calev.   

Abstract

Neuroendocrine and mood responses to a 60 mg oral dose of the serotonin-releasing agent, fenfluramine, were assessed in ten neuroleptic-free, chronic schizophrenic patients and in age- and sex-matched normal control subjects. The prolactin (PRL) response to fenfluramine was significantly blunted in the schizophrenic subjects. Growth hormone and cortisol levels were not differentially affected by the challenge. There was no significant effect of fenfluramine on mood in either group. The blunted PRL response in the schizophrenic group suggests serotonergic dysfunction; possible mechanisms of this finding and implications for treatment are considered.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3154528     DOI: 10.1016/0920-9964(88)90022-9

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  12 in total

Review 1.  The 5-HT receptor--G-protein--effector system complex in depression. I. Effect of glucocorticoids.

Authors:  K P Lesch; B Lerer
Journal:  J Neural Transm Gen Sect       Date:  1991

2.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 3.  Serotonin, dopamine and their interactions in schizophrenia.

Authors:  R S Kahn; M Davidson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

5.  Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects.

Authors:  Stefan Cohrs; Kathrin Pohlmann; Zhenghua Guan; Wolfgang Jordan; Andreas Meier; Gerald Huether; Eckart Rüther; Andrea Rodenbeck
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

6.  The biochemical womb of schizophrenia: A review.

Authors:  N Gaur; S Gautam; M Gaur; P Sharma; G Dadheech; S Mishra
Journal:  Indian J Clin Biochem       Date:  2008-12-20

7.  The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine.

Authors:  H Y Meltzer; M Maes; M A Lee
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 8.  Antibodies as molecular probes in neurobiology. Identification of chemically defined neurons and synapses in tissues and tissue cultures.

Authors:  J Pecci Saavedra; A Brusco; J J López-Costa; L A Gómez; E M López
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

Review 9.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

Authors:  S Grant; A Fitton
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 10.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.